VascVersa

Executive Summary

VascVersa is a private regenerative medicine company spun out of Queen's University Belfast in 2018, leveraging over 20 years of research to develop cell therapies that promote vascular regeneration and repair. The company addresses critical unmet needs in cardiovascular and ischemic diseases, where limited treatment options exist. VascVersa's platform aims to harness progenitor cells to restore blood flow and tissue function, targeting conditions such as peripheral artery disease, myocardial ischemia, and wound healing. With a strong academic foundation and a focus on vascular biology, the company is well-positioned to advance its lead candidate through preclinical and early clinical stages. Given its early-stage profile, VascVersa's value hinges on upcoming proof-of-concept data and strategic partnerships. The company operates in the competitive cell therapy landscape but differentiates through its specific vascular focus. Key risks include technical validation, manufacturing scalability, and financing. However, the large unmet medical need and potential for disease-modifying therapies support a moderate conviction. Success in initial clinical studies or securing non-dilutive funding could significantly de-risk the platform.

Upcoming Catalysts (preview)

• Q4 2026First-in-human clinical trial initiation for lead vascular regeneration candidate40% success
• Q2 2026Series A financing round to advance pipeline50% success
• Q3 2026Publication of preclinical efficacy data in peer-reviewed journal70% success